(NASDAQ: NUVA) Nuvasive's forecast annual revenue growth rate of 7.85% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.4%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.33%.
Nuvasive's revenue in 2023 is $1,201,942,000.On average, 5 Wall Street analysts forecast NUVA's revenue for 2023 to be $68,243,283,277, with the lowest NUVA revenue forecast at $67,622,197,061, and the highest NUVA revenue forecast at $68,904,035,504. On average, 3 Wall Street analysts forecast NUVA's revenue for 2024 to be $72,914,999,849, with the lowest NUVA revenue forecast at $72,900,386,056, and the highest NUVA revenue forecast at $72,941,095,908.
In 2025, NUVA is forecast to generate $77,807,489,084 in revenue, with the lowest revenue forecast at $77,807,489,084 and the highest revenue forecast at $77,807,489,084.